Condition: Locally Advanced Breast Cancer · Metastatic Breast Cancer · Sponsor: Hoffmann-La Roche
The main purpose of this study is to evaluate the effectiveness of inavolisib based regimen in participants with endocrine-resistant, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA)-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) locally advanced or metastatic breast cancer (LA/mBC), following on or after completing adjuvant endocrine therapy in routine clinical practice in China.
This description comes directly from the study's public registry record.
Reference Study ID Number: ML46361 https://forpatients.roche.com/ No attachments to email below. · 888-662-6728 · global-roche-genentech-trials@gene.com
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Xiamen University | Xiamen, Fujian, China | Recruiting |
| Gansu Provincial Maternal and Child Health Hospital (Gansu Provincial Hospital of Traditional Chinese Medicine) | Lanzhou, Gansu, China | Recruiting |
| The First Hospital of Jilin University | Changchun, Jilin, China | Recruiting |
| Wenzhou Medical University Affiliated Second Hospital | Wenzhou, Zhejiang, China | Recruiting |
| Peking University First Hospital | Beijing, China | Recruiting |
| Peking University Third Hospital | Beijing, China | Recruiting |
| Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital | Chengdu, China | Recruiting |
| Chongqing Cancer Hospital | Chongqing, China | Recruiting |
| Sun Yat-sen Memorial Hospital | Guangzhou, China | Recruiting |
| Zhujiang Hospital, Southern Medical University | Guangzhou, China | Recruiting |
| Guangdong Provincial Traditional Chinese Medicine Hospital | Guangzhou, China | Recruiting |
| Guizhou Provincial People's Hospital | Guiyang, China | Recruiting |
+ 16 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07347600